FOLH1 and posterior cortical atrophy: Although clinical studies have shown that these molecular probes possess high sensitivity and specificity in the initial diagnosis of PCa, monitoring of disease progression and response to therapeutic treatment, none of them exceeds the accuracy and sensitivity of the PSMA PET radiopharmaceuticals [18,19].